Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Affiliations

• ¹ German Cancer Consortium (DKTK) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
• ² Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany.
• ³ National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany.
• ⁴ Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
• ⁵ Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany.
• ⁶ DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany.
• ⁷ Department of Neurology, University Hospital and Medical Faculty Mannheim, Mannheim, Germany.
• ⁸ Molecular Biophysics, Center for Integrative Physiology and Molecular Medicine, School of Medicine, Saarland University, Homburg, Germany.
• ⁹ Broad Institute of Harvard and MIT and Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
• ¹⁰ FlowCore Mannheim and Institute of Transfusion Medicine and Immunology, Mannheim, Germany.
• ¹¹ DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany.
• ¹² Institute of Neurology, Medical University of Vienna, Vienna, Austria.
• ¹³ CNS Tumors Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
• ¹⁴ Agios Pharmaceuticals, Inc., Cambridge, MA, USA.
• ¹⁵ Department of Diagnostic and Interventional Neuroradiology, Neuro-Kopf-Zentrum, Klinikum rechts der Isar, Technical University Munich, Munich, Germany.
• ¹⁶ Department of Neuroradiology, Heidelberg University Medical Center, Heidelberg, Germany.
• ¹⁷ Max Eder Junior Group on Low Grade Gliomas, Heidelberg University Medical Center, Heidelberg, Germany.
• ¹⁸ DNA Vectors Unit, DKFZ, Heidelberg, Germany.
• ¹⁹ Center for Organismal Studies, University Heidelberg, Heidelberg, Germany.
• ²⁰ Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
• ²¹ Department for Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
• ²² Department of Neurosurgery, Stuttgart Clinics, Stuttgart, Germany.
• ²³ Department of Neurosurgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
• ²⁴ Dr. Senckenberg Institute of Neurooncology, Goethe University Hospital, Frankfurt, Germany.
• ²⁵ DKTK Partner Site Frankfurt/Mainz, Frankfurt, Germany.
• ²⁶ Institute of Neurology (Edinger Institute), University Hospital and Medical Faculty, Goethe University, Frankfurt, Germany.
• ²⁷ Neurosurgery Clinic, University Hospital Mannheim, Mannheim, Germany.
• ²⁸ Division of Biostatistics, DKFZ, Heidelberg, Germany.
• ²⁹ Metabolic Center Heidelberg, University Children's Hospital, Heidelberg, Germany.
• ³⁰ Division of Experimental Neurosurgery, Department of Neurosurgery, Heidelberg University Medical Center, Heidelberg, Germany.
• ³¹ Research and Development, Pharmaceuticals, Bayer AG, Berlin, Germany.
• ³² Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• ³³ German Cancer Consortium (DKTK) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [email protected].
• ³⁴ Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany. [email protected].
• ³⁵ National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany. [email protected].
• ³⁶ Department of Neurology, University Hospital and Medical Faculty Mannheim, Mannheim, Germany. [email protected].